Given that DNA damaging agents have been widely exploited for anticancer activities, targeting properly spaced di-adducts or a cluster-like drug that effectively stalls XPC or other damage recognition proteins could lead to strong resistance to repair and, thus, a higher efficiency in killing cancer cells. Here, XPC is linked to cancer.